17 results about "A serotype" patented technology

The invention discloses an indirect ELISA (Enzyme-Linked Immunosorbent Assay) detection kit for distinguishing host infected Listeria monocytogenes and / or Listeria ivanovii. The coating antigens are respectively a recombinant listeria monocytogenes surface protein ActA, a serotype 4h listeria monocytogenes and listeria ivanovii common outer membrane protein SmcL and a listeria ivanovii specific outer membrane protein I-inlH, indirect ELISA methods are respectively established based on the three antigens, the three detection methods are combined to detect the content of the listeria monocytogenes, and the content of the listeria ivanovii can be detected. The levels of the ActA antibody, the SmcL antibody and the I-inlH antibody in a clinical serum sample can be effectively monitored, and the detection on the listeria monocytogenes caused by the listeria monocytogenes and / or the listeria ivanovii is realized. The kit is relatively high in sensitivity, strong in specificity and good in stability, and an effective method is provided for epidemiological investigation and diagnosis of listeria monocytogenes.

The present invention is a serotype determination method. [Subject] To provide a novel serotype determination method for Escherichia coli and the like, which is not subject to the common constraints of indirect methods such as antigen-antibody reaction and gene analysis. [Solution] For example, a serotype determination method for determining the serotype of Escherichia coli, the method comprising the following steps (1) to (3): Step (1), in the spectrum obtained by performing the aforementioned mass spectrometry analysis on the sample, selecting a first peak group consisting of a plurality of peaks detected repeatedly and continuously at equal intervals, and obtaining the difference in m / z values ​​between adjacent peaks of the first peak group as the peak interval measured m / z value of the first peak group; Step (2), comparing the aforementioned peak interval measured value with the m / z value obtained separately; Step (3), based on the result of the aforementioned comparison step, determining the corresponding specific serotype as the serotype of the Escherichia coli.

To provide an improved process related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae (S. pneumoniae) serotype 35B to a carrier protein, and a prepared serotype 35B polysaccharide-protein conjugate.SOLUTION: A serotype 35B S. pneumoniae polysaccharide-protein conjugate has a molecular weight of 1,000 kDa to 7,000 kDa. The conjugate comprises a lysine consumption of 3 mol / mol protein to 9 mol / mol protein. A process for making the conjugate comprises activation of the polysaccharide, wherein the activation utilizes periodate in a range of 0.01 to 0.1 moles of periodate per mole of polysaccharide repeating unit.SELECTED DRAWING: Figure 1A

Disclosed herein are methods for detecting the presence of a plurality of adeno-associated viruses (AAV) or adenoviruses (Ad) in a sample. Also described are methods for determining a plurality of serotypes of AAV or Ad viruses in a sample. Further disclosed are methods to detect the presence of heterogeneous viral capsid proteins in a sample comprising a serotype of AAV or Ad. The use of LC-MS to detect the presence of a plurality of AAV or Ad in a sample; or to determine a plurality of serotypes of a plurality of AAV or Adin a sample; or detect the presence of heterogeneous viral capsid proteins in a sample comprising a serotype of AAV or Ad is also disclosed.

The invention discloses a primer group for amplifying a serotype dengue type II virus genome. The primer group comprises a primer pair 1 to a primer pair 16, and the nucleotide sequences of the 16 primer pairs are sequentially shown as SEQ ID NO: 1 to SEQ ID NO: 32. The invention also discloses a targeted amplification kit which contains the primer group and is used for rapidly amplifying the serotype dengue type II virus. The invention also discloses application of the primer group and the kit in preparation of a product for amplifying a serotype dengue type II virus genome. The invention also discloses a method for rapidly obtaining a serotype dengue type II virus whole genome based on targeted amplification. The targeted amplification primer group consists of 16 pairs of primers, can cover and amplify all current epidemic serotype dengue II virus strains, and is high in amplification efficiency and less in cross interference; meanwhile, genomes obtained by a downstream sequencing method and an analysis method constructed by the amplicon are high in sequencing precision and large in sequencing flux.

The invention belongs to the technical field of vaccine preparation, and particularly relates to a haemophilus parasuis adjuvant vaccine which comprises the following ingredients: serum type 4 haemophilus parasuis liquid, serum type 5 haemophilus parasuis liquid, an alumina gel adjuvant, a composite polysaccharide immunopotentiator, methanol, a solid culture medium and a liquid culture medium. According to the invention, the vaccine stock solution prepared by adding the mixed adjuvant and mixing serum type 4 and type 5 haemophilus parasuis solutions is inactivated and then inoculated to piglets, so that a larger antigen library is formed in the bodies of the piglets, the antigen library is slowly released in the application process, the action time of the antigen is prolonged, and meanwhile, the vaccine has a better promotion effect on the immune effect; the inoculation frequency is reduced, the drug resistance can be alleviated, the cost expenditure of farmers is reduced, and the morbidity and mortality of swinery are reduced.

The invention relates to the field of vaccine preparation, in particular to a bivalent bacterial ghost vaccine and a preparation method thereof.The method comprises the steps that a mixed viable bacterium suspension of pasteurella multocida and mannheimia haemolytica is obtained; adding sodium hydroxide into the mixed bacterial liquid; standing for a period of time, and centrifugally precipitating to obtain a bigeminy bacterial ghost; and finally, uniformly mixing the bivalent bacterial ghost with an aluminum hydroxide adjuvant to obtain the bivalent bacterial ghost vaccine. The method is simple to operate, low in cost and convenient to popularize. On the basis of collecting a clinical sheep pneumonia sample and separating pathogenic bacteria, a serotype strain with more infection and stronger toxicity is subjected to thallus culture, a virulent strain of an epidemic serotype is screened as a vaccine strain, and a pasteurella multocida and mannheimia haemolytica bigeminy ghost vaccine for coping with an epidemic predominant serotype is prepared; production is protected, and the breeding benefits of the sheep farm are improved.

Disclosed herein are methods for detecting the presence of a plurality of adeno-associated viruses (AAVs) or adenoviruses (Ad) in a sample. Methods for determining multiple serotypes of AAV or Ad virus in a sample are also described. Further disclosed are methods for detecting the presence of a heteroviral capsid protein in a sample comprising a serotype of AAV or Ad. Also disclosed is the use of LC-MS for detecting the presence of a plurality of AAVs or Ad in a sample; or a use for determining a plurality of serotypes of a plurality of AAVs or Ad in a sample; or to detect the presence of a heteroviral capsid protein in a sample comprising a serotype of AAV or Ad.

The invention discloses a subunit vaccine for serum type 4, type 8 and type 11 fowl adenoviruses and application of the subunit vaccine. The immunogenic composition comprises three antigen proteins with amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3. The invention also discloses a subunit vaccine which contains the three antigen proteins and is used for preventing diseases caused by avian adenovirus infection. Experiments show that after the subunit vaccine is used for immunizing chicken, the chicken can be protected from infection or attack of the fowl adenovirus, the immune response of the body can be effectively activated, complete immune challenge protection is generated, and the protection rate reaches 100%. The strain can completely resist the attack of virulent virus without diseases, and has good practical application value. The subunit vaccine provided by the invention has the characteristics of high antigen expression quantity, high antigen stability, high purity, good safety and strong immunogenicity, and lays a solid foundation for industrial production of avian adenovirus multivalent subunit vaccines and diagnostic reagents.

The invention discloses a method for simultaneously producing multiple recombinant adeno-associated viruses, and belongs to the field of gene therapy. Comprising the following steps: stably integrating multiple target genes into a host cell genome or stably integrating capsid protein Cap genes of multiple serotypes into the host cell genome; screening monoclonal cells of capsid protein Cap genes which stably express target genes or stably express serotypes; the method comprises the following steps: co-transfecting a transfer plasmid containing an AAV reverse terminal repetitive sequence, a Rep gene plasmid and an adenovirus auxiliary gene plasmid into a monoclonal cell of a capsid protein Cap gene for stably expressing a target gene or stably expressing a serotype; and harvesting and purifying the recombinant AAV virus to obtain an AAV virus mixture with a specific proportion of target genes or a hybrid AAV virus with a specific proportion of capsid proteins.

The invention relates to the technical field of molecular diagnosis, and discloses a specific primer for identifying a vibrio parahaemolyticus KUT1 type strain and a fluorescent PCR (Polymerase Chain Reaction) detection method. The invention provides a primer KUT1-F / R and a TaqMan probe for identifying a vibrio parahaemolyticus KUT1 type strain, and establishes a fluorescent PCR (Polymerase Chain Reaction) method (TaqMan probe method). According to the method, the KUT type of the main vibrio parahaemolyticus epidemic in diarrhea patients in China can be quickly identified, a serotyping system of the vibrio parahaemolyticus is expanded, and a more accurate tool is provided for epidemiological investigation and traceability. Compared with the prior art, the kit has the advantages that the due level of a fluorescent PCR technology is achieved in the aspects of amplification efficiency, sensitivity and specificity, so that efficient and specific detection on the KUT strain is realized, whether the strain is the mainly popular KUT type in China or not can be judged within one hour, and the actual use detection requirement is fully met.

This invention provides a serotyping method, a serotyping PCR kit, and a primer pair for Mannhemia haemolitica, enabling simple and rapid serotyping of the species. [Solution] For the 12 serotypes of Mannhemia haemolitica (A1, A2, A5, A6, A7, A8, A9, A12, A13, A14, A16, A17), 11 specific capsule-coding genes are targeted, with serotypes A14 and A16 having homologous capsule-coding genes.

The invention provides an adeno-associated virus gene vector with a serotype of AAV.hu.S17 and application of the adeno-associated virus gene vector. The compound is applied to preparation of drugs for infecting brain nerve cells and retina nerve cells. The AAV.hu.S17 has higher infection characteristics of in-vivo brain nerve cells and retinal photoreceptor cells than the AAV2, and the AAV.hu.S17 has higher infection characteristics of in-vivo brain nerve cells and retinal photoreceptor cells. The retina of a mouse is infected through vitreous injection, AAV.hu.S17 is more prone to infection of retinal pigment epithelial cells (RPE) and retinal photoreceptor cells (PRC), and basically does not infect optic ganglion cells (RGC) on the inner layer; and compared with AAV2, the compound has higher infection selectivity, and the efficiency of infecting retina photoreceptor cells is higher than that of AAV2. The novel AAV.hu.S17 serotype provided by the invention can be used as a virus vector tool for basic scientific research such as brain science research, and also can be further developed into a vector for gene therapy of brain diseases and ophthalmic retinal diseases.

The invention relates to the technical field of molecular diagnosis, and discloses a specific primer for identifying a vibrio parahaemolyticus KUT2 type strain and a fluorescent PCR (Polymerase Chain Reaction) detection method. The invention provides a primer KUT2-F / R and a TaqMan probe for identifying a vibrio parahaemolyticus KUT2 type strain, and establishes a fluorescent PCR (Polymerase Chain Reaction) method (TaqMan probe method). According to the method, the KUT type of the main vibrio parahaemolyticus epidemic in diarrhea patients in China can be quickly identified, a serotyping system of the vibrio parahaemolyticus is expanded, and a more accurate tool is provided for epidemiological investigation and traceability. Compared with the prior art, the kit has the advantages that the due level of a fluorescent PCR technology is achieved in the aspects of amplification efficiency, sensitivity and specificity, so that efficient and specific detection on the KUT strain is realized, whether the strain is the mainly popular KUT type in China or not can be judged within one hour, and the actual use detection requirement is fully met.

Applications of adeno-associated virus (AAV) vectors in large animal studies and clinical trials generally require high titer and high potency vectors fabricated in scales that can support large doses and / or large populations. Many currently used methods for producing vectors for transient transfection or assisted viral infection based on cell lines have the advantages and limitations thereof. Herein, we report novel methods and compositions for high titer AAV production, which have several key improvements and advantages: (1) a therapeutic AAV vector cassette is cloned in one step into a serotype specific packaging plasmid; and (2) carrying out single plasmid transfection and selection on the stable AAV vector production cell line.

The present invention relates to novel immunogenic compositions comprising conjugated capsular saccharide antigens of Streptococcus pneumoniae (glycoconjugates) and uses thereof. The immunogenic compositions of the invention will generally comprise at least one saccharide conjugate from a serotype of Streptococcus pneumoniae that is not found in Prevnar, Synflorix and / or Prevnar 13. The invention also relates to the use of the novel immunogenic compositions for vaccinating human subjects, particularly infants and the elderly, against pneumococcal infection.

The present invention relates to the field of chemical synthesis, and disclosed is a chemical synthesis method for a serotype O5 O-antigen oligosaccharide of pseudomonas aeruginosa. In the present invention, a D-glucuronic acid building block and a D-fucosamine building block are used to construct an O-antigen trisaccharide, wherein the stereoselective synthesis of a D-fucosamine 1,2-α-cis-glycosidic bond relies on remote acyl participation and reagent regulation, and the synthesis of two 2,3-diaminomannuronic acid 1,2-β-trans glycosidic bonds is realized by means of SN2 nucleophilic substitution of a C2 azido group; and by means of selective assembly of protecting groups, orthogonal modification of modifying groups, and regulation of the reactivity of glycosyl donors and acceptors, the preparation of a multifunctionally modified O-antigen target trisaccharide is successfully completed. The method of the present invention is characterized in that raw materials are cheap and easily available and the preparation method is simple and easy to repeat, and has good prospects of application in the development of vaccines against pseudomonas aeruginosa.